Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension

Interactive Cardiovascular and Thoracic Surgery

Volumn 6, Issue 6, 2007, Pages 715-719

  Tayama, Eiki ^a   Ueda, Tomohiro ^a   Shojima, Takahiro ^a   Akasu, Koji ^a   Oda, Takeshi ^a   Fukunaga, Shuji ^a   Akashi, Hidetoshi ^a   Aoyagi, Shigeaki ^a  

^a KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Arginine vasopressin; Low systemic vascular resistance; Post cardiac surgery management; Pulmonary hypertension

Indexed keywords

ARGIPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; VASOCONSTRICTOR AGENT;

ADULT; AGED; AORTA; AORTA BALLOON; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTINUOUS INFUSION; HEART INDEX; HEART OUTPUT; HEART SURGERY; HUMAN; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; OXYGENATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STATISTICAL SIGNIFICANCE; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE; TREATMENT RESPONSE;

ADULT; AGED; ARGININE VASOPRESSIN; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 37349114816     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2007.159624     Document Type: Article

References (14)

1. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000;15:347-353.
2. Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD, Smith CR, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-980.
3. Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock. A prospective, randomized, controlled study. Circulation 2003;107:2313-2319.
4. Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33:2659-2666.
5. Forrest P. Vasopressin and shock. Anaesth Intensive Care 2001;29:463-472.
6. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasoporessin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96(Suppl):II286-290.
7. Howel J, Whetley M. Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol 1995;25:1143-1152.
8. Tetsuka T, Nakaya Y, Inoue I. Arginine vasopressin inhibits interleukin-1 beta-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hyper 1997;15:627-632.
9. Salzman AL, Vromen A, Denenberg A, Szabo C. K ATP-channel inhibition hemorrhagic shock. Am J Physiol 1997;272:H688-694.
10. Evora PR, Pearson PH, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor mediated production of nitric oxide. Chest 1993;103:1241-1245.
11. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Hirooka Y, Ando S, Takeshita A. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels. J Clin Invest 1993;93:1483-1490.
12. Edwards RM, Rinza W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989;256:F274-278.
13. Edwards RM. Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol 1983;244:F526-534.
14. Loeckinger A, Kleinsasser A, Wenzel V, Mair V, Keller C, Kolbitsch C, Recheis W, Schuster A, Lindner KH. Pulmonary gas exchange after cardiopulmonary resuscitation with either vasopressin or epinephrine. Crit Care Med 2002;30:2059-2062.